What do systematic reviews say?

Effect on later sexual function · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Body image · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Sexual self‐efficacy scale · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Sexual knowledge · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Participant satisfaction · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Quality of life · adult women, 18 years of age or older, who tested positive for a pathogenic mutation in BRCA1 or BRCA2 and who had had risk‐reducing surgery

Measures of psychosocial factors · female BRCA carriers post‐risk‐reducing surgery

Psychosocial effects Measured at 5‐8 weeks (short term); end scores. Positive SMD values signify better psychosocial effects. · adults with breast or prostate cancer receiving radiation therapy alone

Menopause‐specific quality of life (quality of life) · female BRCA carriers post‐risk‐reducing surgery

Effect on later sexual function · female BRCA carriers post‐risk‐reducing surgery

Sexual distress (sexual distress) · female BRCA carriers post‐risk‐reducing surgery

Vasomotor symptoms (vasomotor) · female BRCA carriers post‐risk‐reducing surgery

Physical symptoms (physical) · female BRCA carriers post‐risk‐reducing surgery

Sexual symptoms (sexual) · female BRCA carriers post‐risk‐reducing surgery

Body image · female BRCA carriers post‐risk‐reducing surgery